Investor Newsletter

Issue 05 2024

MicroPort®

01

MicroPort® Donates Medical Devices for El Salvador's First TAVI in a Public Hospital

MicroPort® announced a donation of medical devices worth $50,000 to Rosales National Hospital in El Salvador as part of its commitment to broaden the accessibility of high quality medical solutions worldwide. The donated equipment includes MicroPort® Coronary's coronary stent system and MicroPort® CardioFlow's Transcatheter Aortic Valve Implantation (TAVI) solutions.

The medical team at Rosales National Hospital expressed their willingness to continue collaborating with MicroPort®. Dr Yan Wang highlighted MicroPort®'s ongoing commitment to advancing global cardiovascular treatment and expressed hope that this donation would elevate the medical standards at Rosales National Hospital. He also emphasized the ongoing training programs for Salvadoran doctors provided by Xiamen Cardiovascular Hospital Xiamen University, aimed at collaborating with the Salvadoran medical team to enhance patient care.

Dr Carlos expressed gratitude towards MicroPort® and experts for supporting El Salvador: "We believe that with this donation and academic exchanges, more Salvadoran patients will benefit, and the Salvadoran healthcare system will be significantly enhanced."

MicroPort

MicroPort® CardioFlow Receives Approval for VitaFlow Liberty® in the EU

MicroPort® CardioFlow has obtained CE certification for its second-generation transcatheter aortic valve implantation (TAVI) product, VitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty®). This establishes it as the first Chinese TAVI solution to receive approval in the EU.

As the world's only electrically retrievable transcatheter aortic valve system, VitaFlow Liberty® inherits the design of VitaFlow®. It features a hybrid density self-expanding stent, bovine pericardial valve leaflets, and a high double-layer PET skirt design. This design offers robust radial support, improved coaxial release, and effectively reduces the incidence of perivalvular leakage and regurgitation post-operation. Moreover, its breakthrough upgraded delivery system incorporates a unique and innovative double-reinforced spiral structure that ensures rapid, stable, and precise release and retrieval. This system also provides flexibility, allowing for 360-degree bending of the valve segment.

Mr. Jeffrey Lindstrom, President of MicroPort® CardioFlow, stated that, “Currently, the VitaFlow® series has been utilized in over 10,000 clinical applications worldwide. Moreover, the third generation of VitaFlow®, VitaFlow® III, has also recently demonstrated outstanding results in its First-In-Man clinical trial.” Mr. Guoming Chen, Chairman of MicroPort® CardioFlow, remarked that, “This CE certification is a critical milestone in our company’s global strategic expansion. It will significantly enhance our competitive position in the market.”



MicroPort

MicroPort® MedBot™'s SkyWalker™ Robot Surpasses 1,100 Surgeries Worldwide

Recently, the SkyWalker™ Surgical Robot (SkyWalker™), developed by MicroPort® NaviBot®, an associated company of MicroPort® MedBot™, surpassed 1,100 Total Knee Arthroplasty (TKA) surgeries. SkyWalker™ is now utilized in the orthopedic, joint surgery, and sports medicine departments of nearly 70 hospitals worldwide, including 10 leading medical institutions in the United States and Europe.

Through its clinical applications, SkyWalker™ has been proven to meet diverse global clinical needs and has gained broader recognition among medical professionals. On 14 November, 2023, follow-up data from a clinical study by MicroPort® MedBot™ in primary TKA showed that SkyWalker™ performed comparably to the field's leading robot in terms of the accuracy of lower limb alignment, operation time, estimated blood loss, and results of postoperative clinical and functional knee assessment at 6-month and 1-year follow-ups.

Finally, some experts have praised SkyWalker™ for its high operability and adaptability. They have noted its simple installation and high efficiency, highlighting the positive impact that SkyWalker™ has in the field. This sentiment is echoed by Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort® MedBot™, who remarked: "We will continue to accumulate clinical data for SkyWalker™ and conduct cutting-edge research on digital orthopedic technology centered around surgical robots. This effect aims to promote the integration of advanced technology with surgical robots, driving SkyWalker™'s innovation at the forefront of the global stage."

MOBYBOX®, the World's First Integrated Portable Pneumatic ECMO Product, Completes Its Initial Commercial Applications in Europe

Recently, Hemovent GmbH (Hemovent) announced that its pioneering integrated portable pneumatic extracorporeal membrane oxygenation (ECMO) system, the MOBYBOX®, has completed its first batch of commercial deployments in Europe, successfully showcasing its exceptional portability through multiple intra-hospital and inter-hospital transfers. To date, MOBYBOX® is the only ECMO system to have received Medical Device Regulation Certification. MOBYBOX® has been launched in global markets including Germany, The Netherlands, Italy, Greece, and Israel, and efforts are underway to advance market access in several Middle East Countries as well as in the United States and China.

Dr. Jürgen O. Böhm, CEO & CMO of Hemovent, emphasized that, "Our completely new approach to pump drive, to handle blood flow as well as the safety, simplicity and compactness of the entire ECMO system will allow MOBYBOX® serving both traditional in-hospital settings and mobile medical scenarios, playing a crucial role in scenarios like intra-hospital and outdoor transport, as well as outdoor rescue. We are very proud of our achievements thus far and are actively expanding its market access in more countries, with the aim of extending the benefits of this technology to more patients."

MicroPort

Investor Newsletter

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
First Vice President of Board Secretary and Legal Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com